Omeros Corp OMER:NASDAQ

Last Price$6.62Cboe Real-Time Last Sale as of 11:44AM ET 8/17/22
Cboe Real-Time Quotes
Realtime quote and/or trade prices are not sourced from all markets
Today's Change+0.08(1.22%)
Bid (Size)$6.56 (600)
Ask (Size)$6.62 (7)
Day Low / High$6.49 - 7.20
Volume479.9 K
 

View Pharmaceuticals: Major IndustryPeer Comparison as of 08/17/2022

 

Omeros Corp ( NASDAQ )

Price: $6.62
Change: +0.08 (1.22%)
Volume: 479.9 K
11:44AM ET 8/17/2022
 
 

Ocular Therapeutix Inc ( NASDAQ )

Price: $5.22
Change: -0.10 (1.88%)
Volume: 87.2 K
11:42AM ET 8/17/2022
 
 

IDEAYA Biosciences Inc ( NASDAQ )

Price: $10.02
Change: -0.72 (6.70%)
Volume: 227.4 K
11:47AM ET 8/17/2022
 
 

Eiger BioPharmaceuticals Inc ( NASDAQ )

Price: $9.23
Change: -0.43 (4.45%)
Volume: 36.2 K
11:45AM ET 8/17/2022
 
 

Karyopharm Therapeutics Inc ( NASDAQ )

Price: $5.31
Change: -0.18 (3.28%)
Volume: 276.1 K
11:49AM ET 8/17/2022
 

Read more news Recent News

Omeros Gets FDA Interim Response on Formal Dispute Resolution Request for Narsoplimab
10:40AM ET 8/17/2022 MT Newswires

Omeros (OMER) said Wednesday it has received an interim response from the US Food and Drug Administration on a dispute resolution request for narsoplimab...

Sector Update: Health Care Stocks Remain Lower Ahead of Friday's Close
3:36PM ET 7/29/2022 MT Newswires

Health care stocks remained marginally lower in late Friday trading, with the NYSE Health Care Index down about 0.7% and the SPDR Health Care Select Sector...

Sector Update: Health Care Stocks Retreat in Friday Trading
12:48PM ET 7/29/2022 MT Newswires

Health care stocks were broadly lower in early Friday afternoon trading, with the NYSE Health Care Index down 0.9% and the SPDR Health Care Select Sector...

Omeros Says FDA Grants Orphan Drug Designation to OMS906 to Treat Blood Cell Disease
9:34AM ET 7/29/2022 MT Newswires

Omeros (OMER) said Friday that OMS906 has obtained orphan drug designation from the Food and Drug Administration to treat the rare blood cell disease...

View all Commentary and Analysis

Omeros: Managing An Investment After A Winning Trade
8:30AM ET 8/16/2022 Seeking Alpha

Omeros Corporation (OMER) CEO Gregory Demopulos on Q2 2022 Results - Earnings Call Transcript
8:33PM ET 8/09/2022 Seeking Alpha

Checking Out Chinook Therapeutics
12:03PM ET 7/07/2022 Seeking Alpha

Omeros: Follow The Bouncing Ball
5:42AM ET 7/04/2022 Seeking Alpha

Company Profile

Business DescriptionOmeros Corp. operates as a biopharmaceutical company. The firm engages in the discovery, development, and commercializing of both small-molecule and protein therapeutics for large market. It also offers orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system. The company was founded by Gregory A. Demopulos and Pamela Pierce Palmer on June 16, 1994 and is headquartered in Seattle, WA. View company web site for more details
AddressThe Omeros Building
Seattle, Washington 98119
Phone+1 206 676-5000
Number of Employees236
Recent SEC Filing08/09/20228-K
Chairman, President & Chief Executive OfficerGregory A. Demopulos
Chief Financial Officer, Treasurer & VPMichael A. Jacobsen
Chief Scientific Officer & Vice President-ScienceGeorge A. Gaitanaris
Chief Medical Officer & Vice PresidentJ. Steven Whitaker

Company Highlights

Price Open$6.54
Previous Close$6.54
52 Week Range$1.86 - 16.57
Market Capitalization$415.3 M
Shares Outstanding62.7 M
SectorHealth Technology
IndustryPharmaceuticals: Major
Next Earnings Announcement11/08/2022

Options Summary

Call Open Interest (1d)*
Put Open Interest (1d)*
Call Volume (1d)*
Put Volume (1d)*
Put Call Open Interest Ratio (1d)*
Put Call Volume Ratio (1d)*
* Data delayed by up to 15 minutes

View all fundamentalsFundamentals

Price / Earnings2.30
Earnings per Share-$1.78
Beta vs. S&P 500N/A
Revenue$29.9 M
Net Profit Margin-503.94%
Return on Equity218.70%

Analyst Ratings as of 08/12/2022

Buy
2
Overweight
0
Hold
3
Underweight
0
Sell
1
Consensus RecommendationConsensus Icon
Powered by Factset